Iisrael - heebrea - Ministry of Health

astrazeneca (israel) ltd - durvalumab - תמיסה לאינפוזיה - durvalumab 50 mg/ml - durvalumab

Iisrael - heebrea - Ministry of Health

astrazeneca (israel) ltd - aclidinium bromide - אבקה לשאיפה - aclidinium bromide 0.4 mg - aclidinium bromide

Iisrael - heebrea - Ministry of Health

astrazeneca (israel) ltd - aclidinium as bromide; formoterol fumarate dihydrate - אבקה לשאיפה - formoterol fumarate dihydrate 11.8 mcg; aclidinium as bromide 340 mcg - aclidinium bromide

Iisrael - heebrea - Ministry of Health

astrazeneca (israel) ltd - benralizumab - תמיסה להזרקה - benralizumab 30 mg / 1 ml - benralizumab

Iisrael - heebrea - Ministry of Health

astrazeneca (israel) ltd - trastuzumab deruxtecan - אבקה להכנת תמיסה מרוכזת לעירוי - trastuzumab deruxtecan 100 mg - trastuzumab

Iisrael - heebrea - Ministry of Health

astrazeneca (israel) ltd - tremelimumab - תרכיז להכנת תמיסה לאינפוזיה - tremelimumab 20 mg / 1 ml - tremelimumab

Iisrael - heebrea - Ministry of Health

taro international ltd, israel - esomeprazole - טבליה - esomeprazole 20 mg - esomeprazole - esomeprazole - nexium tablets are indicated for: gastroesophageal reflux disease (gerd): - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (gerd). in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and: - healing of helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with helicobacter pylory associated ulcers. - healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v induced prevention of rebleeding of peptic ulcers.

Iisrael - heebrea - Ministry of Health

taro international ltd, israel - esomeprazole - טבליה - esomeprazole 40 mg - esomeprazole - esomeprazole - nexium tablets are indicated for: gastroesophageal reflux disease (gerd): - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (gerd). in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and: - healing of helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with helicobacter pylory associated ulcers. - healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v induced prevention of rebleeding of peptic ulcers.

Iisrael - heebrea - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - אבקה להכנת תמיסה לזריקה - meropenem as trihydrate 500 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

Iisrael - heebrea - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - אבקה להכנת תמיסה לזריקה - meropenem as trihydrate 500 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.